New drug options are available for advanced CCA, such as the combination of dabrafenib and trametinib has produced promising results for BRAFV600E-mutated CCA (50), and isocitrate dehydrogenase (IDH1) inhibitor has also revealed successful results for biliary tumors (51, 52). Here, IDH1 is linked to cholangiocarcinoma.